Background: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants ...
Major depressive disorder (MDD), perhaps the most common form of depression (APA, 2013), has many subtypes, each with its unique characteristics and treatment needs. I was recently reviewing this with ...
Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some ...
The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...
Major depressive disorder (MDD) not only takes a toll on your mental health, but can also put a strain on your finances. The cost of treating depression in the United States topped $320 billion in ...
Remission (MADRS total score ≤10) was seen in 65% of patients treated with lumateperone in combination with an oral antidepressant, at 6 months. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback